ReviewCurrent rheumatology reports2009
Hypocomplementemic urticarial vasculitis syndrome.
Review in Current rheumatology reports, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 91 citations in OpenAlex.
- Secondary Membranous Nephropathy. A Narrative Review.Frontiers in medicine · 2020Pooled it
- Management of chronic urticaria in children: a clinical guideline.Italian journal of pediatrics · 2019Guideline
- Childhood-onset hypocomplementaemic urticarial vasculitis in France: phenotypic and genotypic diversity in 10 children.Pediatric rheumatology online journal · 2026Article
- Treatment and long-term follow-up of pediatric patients with hypocomplementemic urticarial vasculitis syndrome (HUVS): a case-based review.Clinical rheumatology · 2025Review
- Urticarial hypocomplementemic vasculitis syndrome and systemic lupus erythematosus: a case report and review of the literature.Frontiers in immunology · 2025Review
- A Case of Hypocomplementemic Urticarial Vasculitis Syndrome With Severe Renal and Gastrointestinal Involvement.Cureus · 2024Article
- The many faces of pediatric urticaria.Frontiers in allergy · 2023Review
- Hypocomplementemic Urticarial Vasculitis Syndrome or Systemic Lupus Erythematosus in Evolution?Cureus · 2022Article
- The relevance of complement in pemphigoid diseases: A critical appraisal.Frontiers in immunology · 2022Review
- Hypocomplementemic Atypical IgA Vasculitis: A Case Report.Frontiers in pediatrics · 2022Article
- Review
- Hypocomplementemic urticarial vasculitis syndrome associated with rapidly progressive glomerulonephritis: lessons for the clinical nephrologist.Journal of nephrology · 2021Article
- Urticarial vasculitis.International journal of women's dermatology · 2021Review
- Hypocomplementemic urticarial vasculitis syndrome presenting with bilateral scleritis.BMJ case reports · 2021Article
- Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus.The Journal of experimental medicine · 2021Article
- Kidney Involvement in Hypocomplementemic Urticarial Vasculitis Syndrome-A Case-Based Review.Journal of clinical medicine · 2020Review
- Pathophysiology and therapy of systemic vasculitides.EXCLI journal · 2020Review
- Exceptional association of hypocomplementemic urticarial vasculitis syndrome (HUVS) and symptomatic pulmonary histoplasmosis: a case-based literature review.Clinical rheumatology · 2019Review
- A 36-Year-Old Man With Renal Failure, Fever, and Hypocomplementemia.Arthritis care & research · 2019Article
- Management of Small Vessel Vasculitides.Current rheumatology reports · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypocomplementemic urticarial vasculitis syndrome (HUVS) is an uncommon immune complex-mediated entity characterized by urticaria with persistent acquired hypocomplementemia. First described in 1973, HUVS is associated with several systemic findings including leukocytoclastic vasculitis, severe angioedema, laryngeal edema, pulmonary involvement, arthritis, arthralgia, glomerulonephritis, and uveitis. These manifestations should be present for at least 6 months. Laboratory findings include low complement levels of classical pathway, namely C1q, C2, C3, and C4. The disease marker is the serum presence of anti-C1q antibodies. Treatment, based on disease severity, involves corticosteroids and other immunosuppressive agents that have demonstrated some success. Patients may have significant morbidity and mortality, most commonly caused by chronic obstructive pulmonary disease and acute laryngeal edema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.